Jump to content

IL13RA2

From Wikipedia, the free encyclopedia
(Redirected from CD213A2)

IL13RA2
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesIL13RA2, CD213A2, CT19, IL-13R, IL13BP, interleukin 13 receptor subunit alpha 2
External IDsOMIM: 300130; MGI: 1277954; HomoloGene: 534; GeneCards: IL13RA2; OMA:IL13RA2 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_000640

NM_008356
NM_001306059

RefSeq (protein)

NP_000631

NP_001292988
NP_032382

Location (UCSC)Chr X: 115 – 115.02 MbChr X: 146.17 – 146.21 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Interleukin-13 receptor subunit alpha-2 (IL-13Rα2), also known as CD213A2 (cluster of differentiation 213A2), is a membrane bound protein that in humans is encoded by the IL13RA2 gene.[5]

Function

[edit]

IL-13Rα2 is closely related to IL-13Rα1, a subunit of the interleukin-13 receptor complex. This protein binds IL13 with high affinity, but lacks any significant cytoplasmic domain, and does not appear to function as a signal mediator. It is, however, able to regulate the effects of both IL-13 and IL-4, despite the fact it is unable to bind directly to the latter. It is also reported to play a role in the internalization of IL13.[5]

Clinical Significance

[edit]

IL-13Rα2 has been found to be over-expressed in a variety of cancers, including pancreatic, ovarian, melanomas, and malignant gliomas. [6][7][8][9]

See also

[edit]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000123496Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000031289Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b "Entrez Gene: IL13RA2 interleukin 13 receptor, alpha 2".
  6. ^ Fujisawa T, Joshi B, Nakajima A, Puri RK (November 2009). "A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis". Cancer Research. 69 (22): 8678–85. doi:10.1158/0008-5472.CAN-09-2100. PMID 19887609.
  7. ^ Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK (September 2006). "Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy". Cancer. 107 (6): 1407–18. doi:10.1002/cncr.22134. PMID 16902988. S2CID 70773746.
  8. ^ Okamoto H, Yoshimatsu Y, Tomizawa T, Kunita A, Takayama R, Morikawa T, Komura D, Takahashi K, Oshima T, Sato M, Komai M, Podyma-Inoue KA, Uchida H, Hamada H, Fujiu K, Ishikawa S, Fukayama M, Fukuhara T, Watabe T (February 2019). "Interleukin-13 receptor α2 is a novel marker and potential therapeutic target for human melanoma". Scientific Reports. 9 (1): 1281. Bibcode:2019NatSR...9.1281O. doi:10.1038/s41598-019-39018-3. PMC 6362032. PMID 30718742.
  9. ^ Joshi BH, Plautz GE, Puri RK (March 2000). "Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas". Cancer Research. 60 (5): 1168–72. PMID 10728667.

Further reading

[edit]
[edit]


This article incorporates text from the United States National Library of Medicine, which is in the public domain.